Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 2.269
Filtrar
2.
Res Social Adm Pharm ; 17(1): 1799-1806, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-33317760

RESUMEN

BACKGROUND: Since the start of the new Coronavirus (COVID-19) outbreak in December 2019, pharmacists worldwide are playing a key role adopting innovative strategies to minimize the adverse impact of the pandemic. OBJECTIVES: To identify and describe core services provided by the pharmacist during the COVID-19 pandemic. METHODS: A literature search was performed in MEDLINE, Embase, Scopus, and LILACS for studies published between December 1st, 2019 and May 20th, 2020 without language restriction. Studies that reported services provided by pharmacists during the COVID-19 pandemic were included. Two independent authors performed study selection and data extraction with a consensus process. The pharmacist's intervention identified in the included studies were described based on key domains in the DEPICT v.2. RESULTS: A total of 1189 records were identified, of which 11 studies fully met the eligibility criteria. Most of them were conducted in the United States of America (n = 4) and China (n = 4). The most common type of publication were letters (n = 4) describing the workplace of the pharmacist in hospitals (n = 8). These findings showed the different roles of pharmacists during the COVID-19 pandemic, such as disease prevention and infection control, adequate storage and drug supply, patient care and support for healthcare professionals. Pharmacists' interventions were mostly conducted for healthcare professionals and patients (n = 7), through one-to-one contact (n = 11), telephone (n = 6) or video conference (n = 5). The pharmacists' main responsibility was to provide drug information for healthcare professionals (n = 7) as well as patient counseling (n = 8). CONCLUSIONS: A reasonable number of studies that described the role of the pharmacists during the COVID-19 pandemic were found. All studies reported actions taken by pharmacists, although without providing a satisfactory description. Thus, future research with more detailed description as well as an evaluation of the impact of pharmacist intervention is needed in order to guide future actions in this and/or other pandemic.


Asunto(s)
/terapia , Servicios Farmacéuticos/organización & administración , Farmacéuticos/organización & administración , /epidemiología , Humanos , Rol Profesional
3.
Res Social Adm Pharm ; 17(1): 1838-1844, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-33317762

RESUMEN

BACKGROUND: The newly emerged coronavirus pandemic (COVID-19) has collapsed the entire global health care system. Due to these settings, a lot of strategic changes are adopted by healthcare facilities to ensure continuity in patient-centered services. OBJECTIVE: This study aims to evaluate the effectiveness of structural and operational changes made in ambulatory care pharmacy services during the COVID-19 pandemic. METHODS: A retrospective comparative study was conducted to evaluate the impact and effectiveness of patient-centered interventions and consequent access to medication management care within Johns Hopkins Aramco Health Care ambulatory care pharmacy services during the COVID-19 pandemic by comparing patient-centered key performance indicators before and during COVID-19 pandemic for a total of 4 months. RESULTS: As a result of the structural and operational changes made in patient-centered ambulatory care pharmacy services during the COVID-19 pandemic, a 48% prescriptions requests and 90% prescriptions fills are increased through online health portal application. A three-fold increase in the pharmacy call center utilization resulted in around 10% abandoned calls. In the number of physical visits to ambulatory care pharmacies, a 37% reduction was also noted. The decrease in staff schedule efficiency and an increase in average prescription waiting time were also noticed. The prescription collection through remote area pick up locations, and medication home delivery services were successful during COVID-19 pandemic as supported by statistical data. CONCLUSION: The access to ambulatory care pharmacy services during COVID-19 pandemic has been successfully maintained via medication home delivery, remote area pickup locations, pharmacy call-center consultations and refill requests, online health portal application services, and other measures, while reducing the number of physical visits to the JHAH hospital/clinic to ensure compliance with infection control and prevention measures.


Asunto(s)
Atención Ambulatoria/organización & administración , Atención Dirigida al Paciente/organización & administración , Servicios Farmacéuticos/organización & administración , Atención Ambulatoria/estadística & datos numéricos , Instituciones de Atención Ambulatoria/organización & administración , Accesibilidad a los Servicios de Salud/estadística & datos numéricos , Humanos , Atención Dirigida al Paciente/estadística & datos numéricos , Servicios Farmacéuticos/estadística & datos numéricos , Estudios Retrospectivos
4.
Res Social Adm Pharm ; 17(1): 1929-1933, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-33317767

RESUMEN

The International Pharmaceutical Federation (FIP), as the global leadership body for pharmacists, pharmaceutical scientists and pharmaceutical educators, coordinated and produced as of January 2020 an international response to the COVID-19 pandemic. FIP's response included professional guidance, a programme of digital events and other resources, as well as advocacy and policy tools to support national pharmacists' associations and academic institutions, as well as individual practitioners, in their response at country level. This article describes the strategy adopted by FIP in collaboration with an international group of experts to support the valuable service that pharmacists and their teams provide to communities throughout the pandemic, and their important contribution to easing the huge strain being placed on health systems around the world.


Asunto(s)
/epidemiología , Cooperación Internacional , Servicios Farmacéuticos/organización & administración , Farmacéuticos/organización & administración , Prestación de Atención de Salud/organización & administración , Humanos , Agencias Internacionales , Internacionalidad , Rol Profesional
5.
Rev. esp. med. nucl. imagen mol. (Ed. impr.) ; 39(6): 375-379, nov.-dic. 2020. ilus, graf
Artículo en Español | IBECS | ID: ibc-194659

RESUMEN

En esta publicación se presentan criterios y fundamentos para la organización del trabajo en la práctica segura de la Radiofarmacia Hospitalaria, a fin de minimizar el riesgo de transmisión viral durante la pandemia de COVID-19, en una instalación de referencia de la Comisión Nacional de Energía Atómica de Argentina, mientras se continúan desempeñando servicios esenciales para el sistema de salud. Con este fin se consultaron como referencia documentos de la Comisión Nacional de Energía Atómica, OIEA, la OMS y otras publicaciones científicas. Estas recomendaciones se encuentran en proceso de revisión constante y son actualizadas de manera permanente. En este marco se propone el presente modelo de organización laboral para esta actividad esencial incluyendo recomendaciones generales, particulares y su fundamento epidemiológico e inmunológico


This publication presents criteria and bases for the work organization in the safe practice of Hospital Radiopharmacy, in order to minimize the risk of viral transmission during the COVID-19 pandemic, in a reference facility of the National Energy Commission Atomic of Argentina, while continuing to perform essential services for the health system. For this purpose, documents from the National Energy Commission Atomic, IAEA, WHO and other scientific publications were consulted as reference. These recommendations are under constant review and are permanently updated. Within this framework, the present model of work organization for this essential activity is proposed, including general and specific recommendations and its epidemiological and immunological basis


Asunto(s)
Humanos , Virus del SRAS/patogenicidad , Infecciones por Coronavirus/epidemiología , Radiofármacos/provisión & distribución , Servicios Farmacéuticos/organización & administración , Factores de Riesgo , Infecciones por Coronavirus/prevención & control , Pandemias/estadística & datos numéricos , Argentina/epidemiología , Transmisión de Enfermedad Infecciosa/prevención & control , Precauciones Universales/métodos , Buenas Prácticas de Dispensación
6.
BMC Health Serv Res ; 20(1): 913, 2020 Oct 02.
Artículo en Inglés | MEDLINE | ID: mdl-33008384

RESUMEN

BACKGROUND: Novel Coronavirus is a global pandemic affecting all walks of life and it significantly changed the health system practices. Pharmacists are at the front line and have long been involved in combating this public health emergency. Therefore, the study was aimed to explore pharmacy preparedness and response to prevent and control coronavirus disease 2019 (COVID-19). METHODS: A qualitative study was conducted in six pharmacies in Aksum, Ethiopia in May, 2020. We conducted six in-depth interviews with purposively selected key informants. Direct observation measures were made to assess the activities made in the medicine retail outlets for the prevention and control of the pandemic. Interview data were audio-recorded, translated and transcribed verbatim. Thematic analysis was employed to analyze the data and OpenCode version 4.02 software was used to facilitate the data analysis. RESULTS: The thematic analysis has resulted in seven major themes. Good preparedness measures were undertaken to control and prevent COVID-19. Study informants had good knowledge about the pandemic disease and reported they had used different resource materials to update themselves. Preparing of alcohol-based hand-rub, availing finished sanitizers and alcohol, and advising clients to maintain physical distancing were the major counseling information being delivered to prevent the disease. Some tendencies of irrational drug use and false claims of COVID-19 were observed at the beginning of the pandemic. Interview informants had reported they were working with relevant stakeholders and appropriate patient education and support were given to combat the pandemic. CONCLUSION: The study revealed necessary pharmacy services has been rendered to all clients. However, availability of drugs and medical supplies were scarce which negatively affected the optimal delivery of pharmacy services. The government and other responsible bodies should work together to solve such problems and contain the pandemic.


Asunto(s)
Infecciones por Coronavirus/prevención & control , Pandemias/prevención & control , Servicios Farmacéuticos/organización & administración , Farmacéuticos/psicología , Neumonía Viral/prevención & control , Adulto , Infecciones por Coronavirus/tratamiento farmacológico , Infecciones por Coronavirus/epidemiología , Etiopía/epidemiología , Femenino , Investigación sobre Servicios de Salud , Humanos , Masculino , Persona de Mediana Edad , Preparaciones Farmacéuticas/provisión & distribución , Farmacéuticos/estadística & datos numéricos , Investigación Cualitativa
7.
J Manag Care Spec Pharm ; 26(11): 1468-1474, 2020 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-33119445

RESUMEN

The COVID-19 pandemic and the social unrest pervading U.S. cities in response to the killings of George Floyd and other Black citizens at the hands of police are historically significant. These events exemplify dismaying truths about race and equality in the United States. Racial health disparities are an inexcusable lesion on the U.S. health care system. Many health disparities involve medications, including antidepressants, anticoagulants, diabetes medications, drugs for dementia, and statins, to name a few. Managed care pharmacy has a role in perpetuating racial disparities in medication use. For example, pharmacy benefit designs are increasingly shifting costs of expensive medications to patients, creating affordability crises for lower income workers, who are disproportionally persons of color. In addition, the quest to maximize rebates serves to inflate list prices paid by the uninsured, among which Black and Hispanic people are overrepresented. While medication cost is a foremost barrier for many patients, other factors also propagate racial disparities in medication use. Even when cost sharing is minimal or zero, medication adherence rates have been documented to be lower among Blacks as compared with Whites. Deeper understandings are needed about how racial disparities in medication use are influenced by factors such as culture, provider bias, and patient trust in medical advice. Managed care pharmacy can address racial disparities in medication use in several ways. First, it should be acknowledged that racial disparities in medication use are pervasive and must be resolved urgently. We must not believe that entrenched health system, societal, and political structures are impermeable to change. Second, the voices of community members and their advocates must be amplified. Coverage policies, program designs, and quality initiatives should be developed in consultation with those directly affected by racial disparities. Third, the industry should commit to dramatically reducing patient cost sharing for essential medication therapies. Federal and state efforts to limit annual out-of-pocket pharmacy spending should be supported, even though increased premiums may be an undesirable (yet more equitable) consequence. Finally, information about race should be incorporated into all internal and external reporting and quality improvement activities. DISCLOSURES: No funding was received for the development of this manuscript. Kogut is partially supported by Institutional Development Award Numbers U54GM115677 and P20GM125507 from the National Institute of General Medical Sciences of the National Institutes of Health, which funds Advance Clinical and Translational Research (Advance-CTR), and the RI Lifespan Center of Biomedical Research Excellence (COBRE) on Opioids and Overdose, respectively. The content is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health.


Asunto(s)
Grupos de Población Continentales/estadística & datos numéricos , Infecciones por Coronavirus/epidemiología , Disparidades en el Estado de Salud , Programas Controlados de Atención en Salud/organización & administración , Servicios Farmacéuticos/organización & administración , Neumonía Viral/epidemiología , Afroamericanos , Betacoronavirus , Seguro de Costos Compartidos , Industria Farmacéutica , Grupo de Ascendencia Continental Europea , Honorarios Farmacéuticos , Femenino , Gastos en Salud/estadística & datos numéricos , Accesibilidad a los Servicios de Salud , Hispanoamericanos , Humanos , Masculino , Programas Controlados de Atención en Salud/economía , Cumplimiento de la Medicación , Pandemias , Servicios Farmacéuticos/economía , Estudios Retrospectivos , Factores Socioeconómicos , Estados Unidos/epidemiología
8.
Pharm. pract. (Granada, Internet) ; 18(3): 0-0, jul.-sept. 2020. tab, graf
Artículo en Inglés | IBECS | ID: ibc-194188

RESUMEN

BACKGROUND: Telemedicine is defined as "the use of medical information exchanged from one site to another via electronic communications to improve a patient's health status". This relatively new concept of healthcare is based on the fusion between medical assistance and Information and Communication Technology (ICT) to provide support to people located in remote and underserved areas. It can be found not only in hospitals, but also in other healthcare facilities such as pharmacies. Starting from 2010, telemedicine or telehealth was formally introduced in the Italian pharmaceutical context with the "Pharmacy of Services Decree". In spite of this regulatory framework, the implementation of this technology was very slow and there are no data about the spreading and use of these services in Italian pharmacies. OBJECTIVE: The present study has therefore developed a survey to collect information on the diffusion of telemedicine/telehealth services within Italian pharmacies. METHODS: A two-part questionnaire in Italian was developed using SurveyMonkey, setting a mechanism aimed to have different outcomes according to the answers given. Six hundred eighty-three respondents returned the questionnaire. The results were then analysed statistically. RESULTS: The questionnaire results have shown a limited diffusion of telemedicine/telehealth services among Italian pharmacies and an apparently limited interest of health authorities in supporting the integration of this technology. CONCLUSIONS: More efforts should be spent by national public health stakeholders to better analyse the contribution of telemedicine services available in public pharmacies and to find the best solutions to implement this innovative technology as an established service


No disponible


Asunto(s)
Humanos , Adulto , Persona de Mediana Edad , Telemedicina/métodos , Farmacéuticos , Servicios Farmacéuticos/organización & administración , Servicios Farmacéuticos/tendencias , Telemonitorización , Italia , Encuestas y Cuestionarios
9.
Pharm. pract. (Granada, Internet) ; 18(3): 0-0, jul.-sept. 2020. tab
Artículo en Inglés | IBECS | ID: ibc-194192

RESUMEN

The central role of the Portuguese National Health Service (P-NHS) guarantees virtually free universal coverage. Key policy papers, such as the National Health Plan and the National Plan for Patient Safety have implications for pharmacists, including an engagement in medicines reconciliation. These primary health care reform, while not explicitly contemplating a role for pharmacists, offer opportunities for the involvement of primary care pharmacists in medicines management. Primary care pharmacists, who as employees of the P-NHS work closely with an interdisciplinary team, have launched a pilot service to manage polypharmacy in people living with multimorbidities, involving potential referral to community pharmacy. Full integration of community pharmacy into primary health care is challenging due to their nature as private providers, which implies the need for the recognition that public and private health sectors are mutually complementary and may maximize universal health coverage. The scope of practice of community pharmacies has been shifting to service provision, currently supported by law and in some cases, including the needle and syringe exchange program and generic substitution, remunerated. Key changes envisaged for the future of pharmacists and their integration in primary care comprise the development and establishment of clinical pharmacy as a specialization area, peer clinician recognition and better integration in primary care teams, including full access to clinical records. These key changes would enable pharmacists to apply their competence in medicines optimization for improved patient outcomes


No disponible


Asunto(s)
Humanos , Atención Primaria de Salud/normas , Política de Salud , Farmacias/normas , Farmacéuticos/normas , Servicios Farmacéuticos/normas , Farmacias/organización & administración , Portugal , Servicios Farmacéuticos/organización & administración , Práctica Profesional , Rol Profesional
10.
Pharm. pract. (Granada, Internet) ; 18(3): 0-0, jul.-sept. 2020. graf
Artículo en Inglés | IBECS | ID: ibc-194196

RESUMEN

BACKGROUND: Type 2 diabetes mellitus is a chronic disease that is reaching epidemic proportions worldwide. It is imperative to adopt an integrated strategy, which involves a close collaboration between the patient and a multidisciplinary team of which pharmacists should be integral elements. OBJECTIVE: This work aims to identify and summarize the main effects of interventions carried out by clinical pharmacists in the management of patients with type 2 diabetes, considering clinical, humanistic and economic outcomes. METHODS: PubMed and Cochrane Central Register of Controlled Trials were searched for randomized controlled trials assessing the effectiveness of such interventions compared with usual care that took place in hospitals or outpatient facilities. RESULTS: This review included 39 studies, involving a total of 5,474 participants. Beneficial effects were observed on various clinical outcomes such as glycemia, blood pressure, lipid profile, body mass index and coronary heart disease risk. For the following parameters, the range for the difference in change from baseline to final follow-up between the intervention and control groups was: HbA1c, -0.05% to -2.1%; systolic blood pressure, +3.45 mmHg to -10.6 mmHg; total cholesterol, +10.06 mg/dL to -32.48 mg/dL; body mass index, +0.6 kg/m2 to -1.94 kg/m2; and coronary heart disease risk, -3.0% and -12.0% (among the studies that used Framinghan prediction method). The effect on medication adherence and health-related quality of life was also positive. In the studies that performed an economic evaluation, the interventions proved to be economically viable. CONCLUSIONS: These findings support and encourage the integration of clinical pharmacists into multidisciplinary teams, underlining their role in improving the management of type 2 diabetes


No disponible


Asunto(s)
Humanos , Farmacéuticos/normas , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Competencia Clínica , Servicios Farmacéuticos/normas , Servicios Farmacéuticos/organización & administración , Cumplimiento y Adherencia al Tratamiento , Costos y Análisis de Costo/métodos , Hemoglobina A Glucada/uso terapéutico , Calidad de Vida
11.
Pharm. pract. (Granada, Internet) ; 18(3): 0-0, jul.-sept. 2020. tab, graf
Artículo en Inglés | IBECS | ID: ibc-194197

RESUMEN

BACKGROUND: While pharmacists are well positioned to implement pharmacogenomic testing in healthcare systems, uptake has been limited. OBJECTIVE: The primary objective of this survey was to determine how post-graduate education and training influences pharmacist's knowledge and attitudes of pharmacogenomic testing. METHODS: Survey questions were developed by the study team, and responses were collected electronically using REDCapTM. The electronic survey was sent to all pharmacists (n=161) within a large, multi-state healthcare system by email. RESULTS: A total of 75 (47%) respondents completed all aspects of the survey. The majority of respondents were female (60%), worked in acute care settings (57%), were full-time employees (80%), and worked in an urban area (85%), with many graduating in or after 2010 (43%). For post-graduate education, 36% of respondents completed a Post-Graduate Year One Residency (PGY-1), and 27% had a board certification. Those that completed a PGY-1 residency were significantly more likely to have received formal training or education on pharmacogenomics than those who had not. They also assessed their own knowledge of pharmacogenomic resources and guidelines higher than those without PGY-1 training. More recent graduates were also significantly more likely to have received formal training or education on pharmacogenomics. Additionally, pharmacists who completed a PGY-1 residency were more likely to respond favorably to pharmacogenomics being offered through pharmacy services. Pharmacists with board certification were more comfortable interpreting results of a pharmacogenomic test than those without board certification. CONCLUSIONS: Pharmacists who have completed a PGY-1 residency or received board certification appear more comfortable with interpretation and implementation of pharmacogenomic testing


No disponible


Asunto(s)
Humanos , Masculino , Femenino , Pruebas de Farmacogenómica/tendencias , Conocimientos, Actitudes y Práctica en Salud , Farmacogenética/educación , Servicios Farmacéuticos/normas , Actitud del Personal de Salud , Servicios Farmacéuticos/organización & administración , Encuestas y Cuestionarios , Análisis de Datos
12.
Pharm. pract. (Granada, Internet) ; 18(3): 0-0, jul.-sept. 2020. tab
Artículo en Inglés | IBECS | ID: ibc-194204

RESUMEN

With a primary care physician shortage, utilization of pharmacists in the ambulatory care setting has proven to have positive economic and clinical outcomes for the practice and for patients. To extend the reach of the pharmacists, students may assist with patient care activities, such as medication reconciliation, point-of-care testing, and counseling. Evidence has shown that students benefit in building confidence, as well as improved perceptions of interprofessional care, while positive patient outcomes are maintained. There are many methods for schools to integrate these experiences early into their curriculum, as well as for students to explore opportunities on their own


No disponible


Asunto(s)
Humanos , Estudiantes de Farmacia/estadística & datos numéricos , Educación en Farmacia/métodos , Rol Profesional , Atención Ambulatoria , Servicios Farmacéuticos/organización & administración , Servicios Farmacéuticos/normas
14.
Aust J Gen Pract ; 49(8): 530-532, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-32738870

RESUMEN

BACKGROUND: During the COVID-19 pandemic, vulnerable and older people with chronic and complex conditions have self-isolated in their homes, potentially limiting opportunities for consultations to have medications prescribed and dispensed. OBJECTIVE: The aim of this article is to describe initiatives to ensure ongoing access to medications during the COVID-19 pandemic. DISCUSSION: Cooperation between wholesalers and purchase limits in pharmacies have helped to ensure supply of essential medications. Therapeutic substitution by pharmacists is permitted for specific products authorised by the Therapeutic Goods Administration. Prescribers are permitted to issue digital image prescriptions, and implementation of electronic prescribing has been fast-tracked. Expanded continued dispensing arrangements introduced during the bushfire crises have been temporarily extended. Pharmacists are permitted to provide medication management reviews via telehealth. A Home Medicines Service has been introduced to facilitate delivery of medications to people who are vulnerable or elderly. Anticipatory prescribing and medication imprest systems are valuable for access to end-of-life medications within residential aged care.


Asunto(s)
Infecciones por Coronavirus , Medicamentos Esenciales/provisión & distribución , Accesibilidad a los Servicios de Salud/organización & administración , Administración del Tratamiento Farmacológico , Pandemias , Servicios Farmacéuticos , Neumonía Viral , Anciano , Australia/epidemiología , Betacoronavirus , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/prevención & control , Prescripción Electrónica , Humanos , Administración del Tratamiento Farmacológico/organización & administración , Administración del Tratamiento Farmacológico/tendencias , Afecciones Crónicas Múltiples/terapia , Pandemias/prevención & control , Servicios Farmacéuticos/organización & administración , Servicios Farmacéuticos/tendencias , Neumonía Viral/epidemiología , Neumonía Viral/prevención & control , Telemedicina/métodos , Telemedicina/organización & administración , Telemedicina/tendencias
15.
Rev. Rol enferm ; 43(7/8): 541-546, jul.-ago. 2020. ilus
Artículo en Español | IBECS | ID: ibc-197874

RESUMEN

El inicio de la andadura de nuevos medicamentos antivirales, como el boceprevir y telaprevir, específicos para el tratamiento de la hepatitis C, trajo nuevas esperanzas de curación para los afectados; esperanzas que se concentraron especialmente en un grupo ciudadano con una alta prevalencia de la enfermedad como la población reclusa y que chocaron de frente con las limitaciones que conllevaban: el aumento de los efectos adversos y el considerable aumento del coste del tratamiento. La ineficaz gestión de los tratamientos por parte de las instituciones, centradas más en las reclamaciones entre comunidades autónomas y el Gobierno por la asunción de los costes, revelaron en el seno del conflicto jurídico un problema de fondo con respecto a la prestación farmacéutica en los centros penitenciarios, donde se pusieron de relieve el incumplimiento del trasvase de competencias en materia de sanidad penitenciaria y la anacronía de la normativa penitenciaria en materia de fármacos con respecto a la legislación vigente, así como la desorganización de la prestación farmacéutica en los recintos penitenciarios. Problemas todos ellos que imponen la necesidad de la reflexión sobre la gestión de un sistema sanitario que afecta a una parte de la población privada de libertad y que tiende a ser olvidada


The beginning of the new antiviral drugs, such as boceprevir and telaprevir, specific for the treatment of Hepatitis C, brought new hopes of healing for those affected; hopes that especially affected to a group of people with a high prevalence of the disease, as the inmate population, and that clashed head-on with the limitations that entailed: the increase in side effects and the considerable increase in the cost of treatment. The inefficient management of the treatments by the institutions, focused more on the claims between the Autonomous Communities and the Government for the assumption of the costs, revealed in the heart of the legal conflict a substantive problem regarding the pharmaceutical provision in the prisons, where the breach of the transfer of powers in the field of prison health, and the anachronism of prison regulations regarding drugs with respect to current legislation, as well as the disorganization of pharmaceutical provision in prisons were highlighted. Problems all of them that impose the need for reflection on the management of a health system that affects a part of the population deprived of liberty and that tends to be forgotten


Asunto(s)
Humanos , Hepatitis C Crónica/tratamiento farmacológico , Antivirales/provisión & distribución , Dispensarios de Medicamentos , Negativa al Tratamiento/estadística & datos numéricos , Hepatitis C Crónica/epidemiología , Prisioneros/estadística & datos numéricos , Derechos del Paciente/tendencias , Servicios Farmacéuticos/organización & administración
17.
Farm. hosp ; 44(4): 158-162, jul.-ago. 2020. tab
Artículo en Español | IBECS | ID: ibc-195092

RESUMEN

OBJETIVO: Proponer una definición actualizada de atención farmacéutica, basada en el modelo capacidad-motivación-oportunidad (CMO), así como los elementos clave y las actividades óptimas para su desarrollo que garanticen los más altos niveles de calidad y excelencia en esta actividad profesional. MÉTODO: Se constituyó un grupo de trabajo compuesto por miembros de la Sociedad Española de Farmacia Hospitalaria y farmacéuticos de diferentes ámbitos asistenciales. Se realizó una revisión bibliográfica en PubMed sobre la evidencia científica disponible acerca de modelos de atención farmacéutica y actividades con mayor impacto y facilidad de implantación. Se elaboró una propuesta de definición y se extrajeron las iniciativas elegidas como elementos clave, distribuyéndolas en cada pilar del modelo propuesto. Tras unificar un primer listado de actividades y términos, el grupo de trabajo revisó y realizó correcciones o propuso nuevas actividades. Se consensuaron, adicionalmente, las definiciones de los tres elementos clave del modelo CMO: capacidad-motivación-oportunidad. El borrador final fue enviado a las diferentes sociedades científicas, farmacéuticas y médicas, así como a las asociaciones de pacientes con las que la Sociedad Española de Farmacia Hospitalaria tiene convenio de colaboración, a fin de incorporar nuevas sugerencias y aportaciones antes del consenso final. RESULTADOS: La definición de atención farmacéutica consensuada fue "La actividad profesional por la cual el farmacéutico se vincula con el paciente (y/o cuidador) y el resto de profesionales sanitarios, para aten-der a este en función de sus necesidades, planteando las estrategias para alinear y alcanzar los objetivos a corto y medio/largo plazo en relación a la farmacoterapia e incorporando las nuevas tecnologías y medios disponibles para llevar a cabo una interacción continuada con el mismo, con el fin de mejorar los resultados en salud". Se han identificado 27 elementos clave, distribuidos entre los tres pilares del modelo, para desarrollar esta actividad. CONCLUSIONES: Se ha consensuado una nueva definición de atención farmacéutica que permitirá reenfocar esta actividad profesional y avanzar desde el trabajo multidisciplinar hacia el enfoque longitudinal y multidimensional del paciente


OBJECTIVE: To propose an updated definition of Pharmaceutical Care based on the Capacity-Motivation-Opportunity (CMO) model and on the key elements and optimal activities for its development that guarantee the highest levels of quality and excellence in this professional activity. METHOD: The consensus was developed by a working group composed of members of the Spanish Society of Hospital Pharmacy and other pharmacists from different healthcare fields. A literature review of PubMed was conducted of the available scientific evidence on pharmaceutical healthcare models and activities with the greatest impact and ease of implementation. A working definition was developed and the initiatives chosen as key elements were collected and included in each pillar of the proposed model. After creating an initial list of activities and terms, the working group reviewed it and made corrections or proposed new activities. In addition, the definitions of the three key elements of the CMO model were agreed upon: Capacity-Motivation-Opportunity. In order to incorporate all appropriate suggestions and contributions before finalizing the consensus, the final draft was sent to the different scientific, pharmaceutical, and medical societies as well as patient associations with which the Spanish Society of Hospital Pharmacy has a collaboration agreement. RESULTS: The definition of consensual Pharmaceutical Care was "Any professional activity by which the pharmacist is linked to the patient (and/or caregiver) and other healthcare professionals, to attend to the patient ac-cording to their needs, setting out strategies to align and achieve the short- and medium-/long-term objectives of pharmacotherapy and incorporating new technologies and the means available to continuously interact with the patients in order to improve their health outcomes". In addition, agreement was reached on the definitions of the three key elements of the CMO model. Finally, 27 key elements for the development of pharmaceutical activity were identified and included in the three pillars of the model. CONCLUSIONS: A new definition of Pharmaceutical Care has been agreed upon that refocuses this professional activity, allowing us to advance within the multidisciplinary working approach toward a longitudinal and multidimensional approach to the patient


Asunto(s)
Humanos , Servicios Farmacéuticos/organización & administración , Farmacia/normas , Profesionalismo , Modelos Teóricos , Administración del Tratamiento Farmacológico/organización & administración , Servicios Farmacéuticos/normas , Indicadores de Salud
18.
Farm. hosp ; 44(4): 174-181, jul.-ago. 2020. tab, graf
Artículo en Español | IBECS | ID: ibc-195094

RESUMEN

En la práctica asistencial de los farmacéuticos de hospital resulta imprescindible la utilización de las tecnologías de la información y comunicación en el ámbito de la Telefarmacia. Por lo tanto, la Sociedad Española de Farmacia Hospitalaria considera oportuno definir el término y condiciones de Telefarmacia y comunicar su posicionamiento institucional a través de este documento de posicionamiento: "La Telefarmacia es la práctica farmacéutica a distancia a través del uso de las tecnologías de la información y comunicación". La Telefarmacia incluye como principales actividades: validación terapéutica, documentación clínica, consulta de atención farmacéutica, monitorización terapéutica, seguimiento de la adherencia, formación/información sobre medicamentos, coordinación con profesionales sanitarios y evaluación de resultados en salud. Los procedimientos asistenciales en el ámbito de la Telefarmacia deben regirse por un Procedimiento Normalizado de Trabajo, con documentación en la historia clínica y sin discriminación de acceso a pacientes candidatos. Se consideran cuatro procedimientos principales de Telefarmacia: seguimiento farmacoterapéutico; información y/o formación a pacientes y cuidadores; coordinación con el equipo multidisciplinar a nivel intra y extrahospitalario; dispensación y entrega informada de medicamentos a distancia. La implantación de la Telefarmacia requiere adecuación de medios humanos (formación, capacitación) y tecnológicos (validación, interoperatividad, confidencialidad). Asimismo, debe dar cumplimiento a la legalidad y normativa vigente, tanto a nivel autonómico como estatal. Los procedimientos de Telefarmacia deben también ajustarse a las consideraciones éticas y los códigos deontológicos pertinentes. Debe fomentarse la evaluación de la Telefarmacia a través del uso de indicadores y de la investigación de su repercusión sobre los resultados en salud. Por tanto, la Sociedad Española de Farmacia Hospitalaria considera que la Telefarmacia es una herramienta complementaria y necesaria para la provisión de una Atención Farmacéutica Especializada con el objetivo final de mejorar los resultados en salud y maximizar la seguridad y satisfacción de los pacientes


The use of information and communication technologies have nowadays become part and parcel of hospital pharmacy practice. Against this background, it is hardly surprising that Telepharmacy has sparked the interest of a large number of stakeholders. In this respect, the Spanish Society of Hospital Pharmacy has developed a definition of the concept and outlined the conditions under which Telepharmacy should operate. It has also shared its institutional stance on the subject through a position statement that states that Telepharmacy is the provision of pharmaceutical care at a distance through information and communication technologies. Telepharmacy practice includes activities such as therapeutic validation, drafting of clinical documents, provision of pharmaceutical care, therapeutic follow-up, adherence monitoring, drug education and information, coordination between healthcare providers and evaluation of health outcomes. The clinical tasks performed as part of Telepharmacy practice must adhere to a standardized procedure and revolve around the patient's clinical record. Access to Telepharmacy must be provided without discrimination. The service comprises four main activities: pharmacotherapeutic follow-up; patient and caregiver-directed education and information-dissemination; coordination with healthcare providers from the same or different hospitals; and remote informed home drug delivery. Implementation of Telepharmacy requires an adjustment of human (training and capacity-building) and technological resources (validation, interoperability, confidentiality). It must also comply with the laws and regulations in force both at a regional and a national level. Telepharmacy procedures must also be adapted to the relevant ethical standards and codes of good practice. Appropriate indicators must be used to evaluate the performance of Telepharmacy and its impact on health outcomes. According to Spanish Society of Hospital Pharmacy Telepharmacy is a necessary complemetary tool to provide specialized pharmaceutical care and thereby improve health outcomes and maximize patient safety and satisfaction


Asunto(s)
Humanos , Telemedicina/normas , Servicios Farmacéuticos/organización & administración , Atención Dirigida al Paciente/organización & administración , Telemedicina/métodos , Sociedades Médicas/organización & administración , Servicios Farmacéuticos/normas , Tecnología de la Información , Consulta Remota/organización & administración , Consulta Remota/normas
19.
Farm. hosp ; 44(4): 135-140, jul.-ago. 2020. tab, graf
Artículo en Español | IBECS | ID: ibc-191014

RESUMEN

OBJETIVO: Analizar la situación de la implantación y desarrollo de la telefarmacia aplicada a la atención farmacéutica a pacientes externos de los servicios de farmacia hospitalaria en España durante la pandemia por la COVID-19. MÉTODO: Se envió una encuesta online de 10 preguntas a todos los socios de la Sociedad Española de Farmacia Hospitalaria a las seis semanas del inicio del periodo de confinamiento por la pandemia. Se solicitó una única respuesta por hospital. Se incluyeron preguntas sobre la realización de atención farmacéutica no presencial con dispensación a distancia previa al inicio de la crisis sanitaria, los criterios de selección de pacientes, los procedimientos de envío de medicación y los medios utilizados, el número de pacientes que se han beneficiado de la telefarmacia y el número de envíos realizados. Por último, se identificó la realización o no de teleconsulta previa al envío de medicación y si la actividad quedó registrada. RESULTADOS: Un 39,3% (n = 185) del total de hospitales públicos del Sistema Nacional de Salud pertenecientes a todas las comunidades autónomas respondieron a la encuesta. El 83,2% (n = 154) de los ser-vicios de farmacia hospitalarios no realizaban actividades de atención farmacéutica no presencial con telefarmacia que incluyeran envío de medicación antes del inicio de la crisis sanitaria. En el periodo de estudio se atendieron 119.972 pacientes y se realizaron 134.142 envíos de medicación. La mayoría de los hospitales no utilizaron criterios de selección de pacientes. El 30,2% de los centros seleccionaron en función de las circunstancias personales del paciente. La dispensación domiciliaria y entrega informada (87%; 116.129 envíos) fue la opción utilizada de forma mayoritaria para el envío. Los medios para hacer llegar la medicación fueron, principalmente, la mensajería externa (47%; 87 centros) o medios propios del hospital (38,4%; 71 centros). Un 87,6% de los hospitales realizaron teleconsulta previa al envío de medicación y el 59,6% registró la actividad de telefarmacia en la agenda de citación. CONCLUSIONES: La implantación de la telefarmacia aplicada a la atención a pacientes externos en España durante la pandemia ha sido elevada. Así se ha podido garantizar la continuidad de los tratamientos de un elevado número de pacientes


OBJECTIVE: To analyze the status of the implementation and development of telepharmacy as applied to the pharmaceutical care of outpatients treated at hospital pharmacy services in Spain during the COVID-19 pandemic. METHOD: Six weeks after the beginning of the confinement period, an online 10-question survey was sent to all members of the Spanish Society of Hospital Pharmacists. A single response per hospital was requested. The survey included questions on the provision of remote pharmaceutical care prior to the onset of the health crisis, patient selection criteria, procedures for home delivery of medications and the means used to deliver them, the number of patients who benefited from telepharmacy, and the number of referrals made. Finally, respondents were asked whether a tele-consultation was carried out before sending patients their medication and whether these deliveries were recorded. RESULTS: A total of 39.3% (n = 185) of all the hospitals in the National Health System (covering all of Spain's autonomous regions) responded to the survey. Before the beginning of the crisis, 83.2% (n = 154) of hospital pharmacy services did not carry out remote pharmaceutical care activities that included telepharmacy with remote delivery of medication. During the study period, 119,972 patients were treated, with 134,142 deliveries of medication being completed. Most hospitals did not use patient selection criteria. A total of 30.2% of hospitals selected patients based on their personal circumstances. Home delivery and informed delivery (87%; 116,129 deliveries) was the option used in most cases. The means used to deliver the medication mainly included the use of external courier services (47.0%; 87 hospitals) or the hospital's own transport services (38.4%; 71 hospitals). As many as 87.6% of hospitals carried out teleconsultations prior to sending out medications and 59.6% recorded their telepharmacy activities in the hospital pharmacy appointments record. CONCLUSIONS: The rate of implementation of telepharmacy in outpatient care in Spain during the study period in the pandemic was high. This made it possible to guarantee the continuity of care for a large number of patients


Asunto(s)
Humanos , Servicios Farmacéuticos/organización & administración , Servicio de Farmacia en Hospital/métodos , Pandemias , Infecciones por Coronavirus/epidemiología , Neumonía Viral/epidemiología , Servicios Externos/métodos , Servicio de Farmacia en Hospital/organización & administración , España , Encuestas y Cuestionarios , Telemedicina/tendencias , Infecciones por Coronavirus/prevención & control , Neumonía Viral/prevención & control
20.
Am J Pharm Educ ; 84(6): ajpe8157, 2020 06.
Artículo en Inglés | MEDLINE | ID: mdl-32665728

RESUMEN

The administrative response to the coronavirus identified in 2019 (COVID-19) pandemic for a variety of units housed in the University of Oklahoma College of Pharmacy is described. Continuity of operations, essential vs nonessential personnel, distance learning, online testing procedures for the Doctor of Pharmacy degree program, and the impact on development are discussed.


Asunto(s)
Infecciones por Coronavirus/epidemiología , Educación en Farmacia/organización & administración , Servicios Farmacéuticos/organización & administración , Neumonía Viral/epidemiología , Facultades de Farmacia/organización & administración , Betacoronavirus , Educación a Distancia/organización & administración , Docentes de Farmacia/organización & administración , Humanos , Pandemias , Servicios Farmacéuticos/economía , Facultades de Farmacia/economía
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...